Tag: Tilray

Posted on

Article: A long list of Anson short positions.Good post on Stockhouse here

Article - Media, Publications

A long list of Anson short positions.Good post on Stockhouse here

u/Rubarbarbara, Reddit, 17 March 2021

I have the full post below:We all know how the dirty rats at Anson Funds work. Wash trading, down ticking, spoofing among a host of other dirty tricks the banks let them get away with.

Then we have their army of social media bashers, their relationships with Nate Anderson at Hindenburg Research, Ben Axler at Sprucepoint Capital Management and Andrew Left at Citron Research, amongst many others. All of them in the pay of Moez and Anson Funds.

All working together to destroy companies and profit off their illegal deals.

Read Full Post

Posted on

Article: Tilray hit by $300 million lawsuit over scheme to bankrupt acquisition target

Article - Media, Publications

Tilray hit by $300 million lawsuit over scheme to bankrupt acquisition target

Mark P, 11 December 2019

Cannabis stocks have had a history of being rife with scandals and potential wrongdoings. While it’s unfortunate that the industry has garnered such a reputation, for the most part, this perception has died down a bit in 2019. However, from time to time, a well-known cannabis company will be implicated in something illegal or against the law. That’s what happened today with Tilray (NASDAQ: TLRY), which was hit with a $300 million lawsuit from an acquisition target that claimed Tilray was trying to make them go bankrupt.

While it didn’t make headlines in the financial press, Bloomberg quietly mentioned that Tilray had been hit with a hefty lawsuit from a soap company called Trimax, which argued that the pot company had been trying to bankrupt one of its subsidiaries in order to make it easy to buy them out. Specifically, Trimax claims that Tilray wanted to buy its line of CBD products at a discount.gh cash that is inflated or compromised, and warranty and service costs are understated by at least $11 million.
Continue reading “Article: Tilray hit by $300 million lawsuit over scheme to bankrupt acquisition target”

Posted on

Article: Tilray Slapped With $150 Million Lawsuit Over Alleged Plot to Bankrupt Takeover Target

Article - Media, Publications

Tilray Slapped With $150 Million Lawsuit Over Alleged Plot to Bankrupt Takeover Target

RYAN T., 10 December 2019

Tilray (NASDAQ: TLRY) is facing some serious allegations after Law360 broke a story recently which details the $150 million lawsuit filed against the Canadian licensed producer (LP) in the state of Florida. According to the lawsuit, Tilray allegedly plotted to bankrupt the Trimax Corp. subsidiary Saavy Naturals for the purpose of acquiring it at a reduced valuation to complement its line of CBD infused personal care products. Saavy Naturals was made famous after it appeared on the ABC hit television show Shark Tank.

The complaint claims that Tilray ran an “outrageous” scam through its majority shareholder and private equity firm Privateer Holdings to convince the company’s owners to bankrupt their own company so Tilray could take them over cheaply. Trimax shareholder Joseph Vasquez III lays out the case in a complaint filed in Florida state court on December 2, 2019, which has since been removed to Florida federal court.
Continue reading “Article: Tilray Slapped With $150 Million Lawsuit Over Alleged Plot to Bankrupt Takeover Target”

Posted on

Article: Citron’s Left calls Tilray surge its ‘worst day ever’ in market

Article - Media, Publications

Citron’s Left calls Tilray surge its ‘worst day ever’ in market

David Randall, 12 November 2018

NEW YORK (Reuters) – Andrew Left, one of Wall Street’s most prominent short-sellers, said Tilray Inc gave his firm its “worst day ever in the market” two months ago when its shares almost doubled in one session, but he remains bearish on the Canadian cannabis company.

Left, whose Citron Research has been betting against the stock since it traded in the $70s, was caught unprepared for the surge, which took the stock as high as $300 in intraday trading on Sept. 19, he told the Reuters Global Investment 2019 Outlook Summit in New York on Monday.
Continue reading “Article: Citron’s Left calls Tilray surge its ‘worst day ever’ in market”

Posted on

Article: Lakewood’s Anthony Bozza Recommended Shorting Three Pot Stocks at Robin Hood

Article - Media, Publications

Lakewood’s Anthony Bozza Recommended Shorting Three Pot Stocks at Robin Hood

Joshua Fineman, 30 October 2018

(Bloomberg) — Lakewood Capital Management LP’s Anthony Bozza recommended shorting Tilray Inc., Canopy Growth Corp., and Aurora Cannabis Inc. at the Robin Hood Investors Conference in New York City, according to a person with knowledge of the presentation. Two of these companies, Canopy Growth and Aurora Cannabis, were named new shorts by Lakewood in their fourth-quarter letter to clients in January.

Bozza said that it’s not a matter of if, but when these pot stocks collapse. Tilray shares have reversed about 9 percent for the day’s peak, turning negative around the same time that Bozza was scheduled to present at RobinHood.
Continue reading “Article: Lakewood’s Anthony Bozza Recommended Shorting Three Pot Stocks at Robin Hood”

Posted on

Article: Short-seller Andrew Left’s Citron Research says surge in cannabis company Tilray is ‘beyond comprehension’

Article - Media, Publications

Short-seller Andrew Left’s Citron Research says surge in cannabis company Tilray is ‘beyond comprehension’

Lenore Fedow, 19 September 2018

Tilray Inc (NASDAQ:TLRY) set the cannabis space ablaze following an interview with CNBC’s Jim Cramer, sending its shares surging double digits. But short-seller Andrew Left’s Citron Research had some harsh words to share about the Canadian cannabis company.

Citron Research was previously bullish on Tilray following Constellation Brands Inc‘s (NYSE:STZ) additional US$4bn investment in its rival Canopy Growth Inc (NYSE:CGC, TSX:WEED). Left had said it could be the next marijuana company to get a “white knight at a premium to market.”

The short-seller has cast doubt on other cannabis stocks via Twitter Inc (NYSE:TWTR) as well, including Cronos Group Inc (NASDAQ:CRON, CSE:CRON) and Namaste Technologies Inc (CVE:N, OTCQB:NXTTF). Shares of Tilray soared nearly 50% to US$232 in Wednesday pre-market trading.
Continue reading “Article: Short-seller Andrew Left’s Citron Research says surge in cannabis company Tilray is ‘beyond comprehension’”

Posted on

Article: Our Final Word on $TLRY before $50

Article - Media, Publications

Our Final Word on $TLRY before $50

Citron Research, 12 September 2018

Tilray management is not stupid. Just seven weeks ago Tilray decided to go public with an offering price of $17. This was done with much deliberation between them and their many bankers. With this price Citron believes they took into consideration all future deals and partnerships that the company had been planning.

The recent cannabis stock rally is a US phenomenon fueled by retail investors. Since August 15, US marijuana stocks Tilray and Cronos have significantly outpaced the performance of their Canadian traded peers.

Due to federal regulation, US listed stocks cannot have any operations in the US without losing their listings, whereas Canadian listed stocks can have US operations. The US will be the largest cannabis market in the world. Today, the California market is over 5x larger than all of Canada. Despite obvious logic, we’ve seen US retail investors pile into the US listed marijuana stocks.
Continue reading “Article: Our Final Word on $TLRY before $50”

Posted on

Article: TILRAY: NEXT IN LINE IN A BUDDING CANNABIS INDUSTRY

Article - Media, Publications

TILRAY: NEXT IN LINE IN A BUDDING CANNABIS INDUSTRY

Citron Research, 15 August 2018

On Jan 3, 2018, Citron predicted that Aurora Cannabis would fall from the then $14 to $6.50. It currently trades at $6.19.

Today we state that you would have to be ‘high’ to short any of the marijuana names based on the recent investment by Constellation in to Canopy Growth, the largest investment in the space ($4bn).The premium paid to market shows confidence by Constellation that could rattle any short seller.

The opportunity now lies in finding the next company to get a white knight at a premium to market and to Citron that answer is easy- Tilray.

Citron believes that Tilray is best in class and if it were to get the same multiple we are assigning to Canopy, the stock would be trading at $45 a share.
Continue reading “Article: TILRAY: NEXT IN LINE IN A BUDDING CANNABIS INDUSTRY”

THE DOLLAR HAS NO INTRINSIC VALUE : DO YOUR ASSETS?